-
1.发明公开公开(公告)号：US20230194552A1
公开(公告)日：2023-06-22
申请号：US17935294
申请日：2022-09-26
Applicant: ASTUTE MEDICAL, INC.
Inventor： JOSEPH ANDERBERG , JEFF GRAY , PAUL MCPHERSON , KEVIN NAKAMURA , JAMES PATRICK KAMPF
CPC classification number: G01N33/6893 , G01N33/6863 , G01N33/86 , G01N2333/96447 , G01N2800/52 , G01N2333/4745 , G01N2333/522 , G01N2800/347 , G01N2800/50
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.
-
公开(公告)号：US20230008880A1
公开(公告)日：2023-01-12
申请号：US17409168
申请日：2021-08-23
Applicant: ASTUTE MEDICAL, INC.
Inventor： JOSEPH ANDERBERG , JEFF GRAY , PAUL MCPHERSON , KEVIN NAKAMURA , JAMES PATRICK KAMPF
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.
-
公开(公告)号：US20210025875A1
公开(公告)日：2021-01-28
申请号：US16611456
申请日：2018-05-07
Applicant: ASTUTE MEDICAL, INC.
Inventor： PAUL MCPHERSON , JAMES PATRICK KAMPF
IPC: G01N33/543
Abstract: The present invention provides methods and compositions for managing renal replacement therapy. A risk score, which is determined from a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and/or a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.
-
4.发明公开
公开(公告)号：US20240044914A1
公开(公告)日：2024-02-08
申请号：US18049490
申请日：2022-10-25
Applicant: ASTUTE MEDICAL, INC.
Inventor： JOSEPH ANDERBERG , PAUL MCPHERSON , JEFF GRAY , KEVIN NAKAMURA , JAMES PATRICK KAMPF , THOMAS KWAN
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/96466 , G01N2333/70596 , G01N2800/348 , G01N2333/4703 , G01N2800/347
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Follistatin-related protein 3, Basigin, Cathepsin B, and Tenascin as diagnostic and prognostic biomarker assays in renal injuries.
-
公开(公告)号：US20210148937A1
公开(公告)日：2021-05-20
申请号：US17153200
申请日：2021-01-20
Applicant: ASTUTE MEDICAL, INC.
Inventor： JOSEPH ANDERBERG , JEFF GRAY , PAUL MCPHERSON , KEVIN NAKAMURA , JAMES PATRICK KAMPF
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.
-
6.发明申请
公开(公告)号：US20190353667A1
公开(公告)日：2019-11-21
申请号：US16482778
申请日：2018-02-06
Applicant: ASTUTE MEDICAL, INC.
Inventor： JOSEPH ANDERBERG , PAUL MCPHERSON , JAMES PATRICK KAMPF , KEVIN NAKAMURA , JEFF GRAY , THOMAS KWAN
IPC: G01N33/68
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Angiopoietin-related protein 6, Complement C5, Fibroblast growth factor 21, Fibroblast growth factor 23, Pro-interleukin-16, C—X—C motif chemokine 9, Hepatocyte growth factor-like protein, and/or Tumor necrosis factor receptor superfamily member 1 IB as diagnostic and prognostic biomarker assays in renal injuries.
-
公开(公告)号：US20240027473A1
公开(公告)日：2024-01-25
申请号：US18253293
申请日：2021-11-18
Applicant: ASTUTE MEDICAL, INC.
Inventor： PAUL MCPHERSON , JAMES PATRICK KAMPF , THOMAS KWAN
CPC classification number: G01N33/6893 , G16H20/40 , A61K35/14 , G01N2800/52 , G01N2800/347
Abstract: A method of devising a therapy plan for renal replacement therapy (RRT) includes detecting a level of one or more biomarkers in a body fluid sample obtained from a subject. The level(s) may be correlated to an expected benefit from treatment with continued RRT and/or to an expected ability to successfully discontinue RRT. The method may include the step of assigning the subject to a predetermined subpopulation of individuals exhibiting a known status with regard to meeting criteria for continuing or discontinuing RRT. In some embodiments, the biomarker level is detected by introducing the body fluid into an assay instrument and contacting the body fluid to a binding reagent, for example, an antibody.
-
公开(公告)号：US20220236285A1
公开(公告)日：2022-07-28
申请号：US17613766
申请日：2020-05-22
Applicant: ASTUTE MEDICAL, INC.
Inventor： JAMES PATRICK KAMPF , THOMAS KWAN , PAUL MCPHERSON
IPC: G01N33/68
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed herein are methods, compositions, and kits for detecting C-C motif chemokine 14 in combination with creatinine, urine output, and/or cystatin C for predicting the likelihood of persistent acute kidney injury as well as methods for appropriately treating a subject based on his or her assigned likelihood.
-
公开(公告)号：US20220187319A1
公开(公告)日：2022-06-16
申请号：US17681493
申请日：2022-02-25
Applicant: ASTUTE MEDICAL, INC.
Inventor： JOSEPH ANDERBERG , JEFF GRAY , PAUL MCPHERSON , KEVIN NAKAMURA , JAMES PATRICK KAMPF
IPC: G01N33/68
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member HB, Interleukin-11, Cathepsin D, C-C motif chemokine 24, C-X-C motif chemokine 6, C-C motif chemokine 13, C-X-C motif chemokines-1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.
-
公开(公告)号：US20220155324A1
公开(公告)日：2022-05-19
申请号：US17494773
申请日：2021-10-05
Applicant: ASTUTE MEDICAL, INC.
Inventor： JOSEPH ANDERBERG , PAUL MCPHERSON , JEFF GRAY , KEVIN NAKAMURA , JAMES PATRICK KAMPF , THOMAS KWAN
IPC: G01N33/68
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulin-like growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.
